[Oral, low-dosage methotrexate in chronic progressive multiple sclerosis. A preliminary critical analysis].
Weilbach
F X
FX
Neurologische Klinik und Poliklinik, Universität, Würzburg.
Toyka
K V
KV
Hartung
H P
HP
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009460:Neurologic Examination / Q000187:drug effects; D011446:Prospective Studies
D007166:Immunosuppressive Agents; D008727:Methotrexate
Orales, niedrig dosiertes Methotrexat bei chronisch-progredienter multipler Sklerose. Eine vorläufige kritische Analyse.